Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Evaluation of a Once Every 28 Days Dosing Regimen for LY573636-sodium in Patients With Metastatic Breast Cancer

NCT00992225 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00992225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00992225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Evaluation of a Once Every 28 Days Dosing Regimen for LY573636-sodium in Patients With Metastatic Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
April 30, 2011
Enrollment
43 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer